Sarah Ferber - Orgenesis Chief Scientific Officer
| ORGS Stock | USD 0.50 0.01 1.96% |
Executive
Prof. Sarah Ferber, Ph.D., is Chief Scientific Officer of Orgenesis Inc. Prof. Ferber studied biochemistry at the Technion under the supervision of Professor Avram Hershko and Professor Aharon Ciechanover, winners of the Nobel Prize in Chemistry in 2004. She completed a postdoctoral fellowship at the Joslin Diabetes Lab at Harvard Medical School. Prof. Ferbers breakthrough discovery suggested that humans carry their own stemcells throughout adulthood, thus obviating the need for embryonic stem cells for generating an organ in need. Most of the research was conducted in Prof. Ferbers lab, in the Endocrine Research Lab at the Sheba Medical Center, and currently employs 11 scientists. Prof. Sarah Ferber received TEVA, LINDNER, RUBIN and WOLFSON awards for this research. Prof. Ferbers research work was funded over the past 10 years by the JDRF, the Israel Academy of Science foundation and DCure. since 2012.
| Age | 59 |
| Tenure | 12 years |
| Address | 20271 Goldenrod Lane, Germantown, MD, United States, 20876 |
| Phone | 480 659 6404 |
| Web | https://www.orgenesis.com |
Orgenesis Management Efficiency
The company has return on total asset (ROA) of (0.6505) % which means that it has lost $0.6505 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.3908) %, meaning that it created substantial loss on money invested by shareholders. Orgenesis' management efficiency ratios could be used to measure how well Orgenesis manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Orgenesis' Return On Tangible Assets are comparatively stable compared to the past year. Return On Assets is likely to gain to 3.99 in 2024, despite the fact that Return On Capital Employed is likely to grow to (3.36). At this time, Orgenesis' Non Currrent Assets Other are comparatively stable compared to the past year. Other Assets is likely to gain to about 1.8 M in 2024, whereas Total Current Assets are likely to drop slightly above 15.1 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Stephen Yu | Aerovate Therapeutics | N/A | |
| BSc MD | Aerovate Therapeutics | N/A | |
| Graeme Currie | Pasithea Therapeutics Corp | 57 | |
| Bruce Close | Acrivon Therapeutics Common | N/A | |
| James Taylor | Achilles Therapeutics PLC | 63 | |
| MaryAlice JD | Acrivon Therapeutics Common | 50 | |
| Erin OBoyle | Rezolute | N/A | |
| MiKyung Kim | Neurobo Pharmaceuticals | N/A | |
| Ling Zhou | Adagene | N/A | |
| Michael Palmieri | Tango Therapeutics | N/A | |
| John MS | Tango Therapeutics | N/A | |
| Shree Patel | Achilles Therapeutics PLC | N/A | |
| Sankaram Mantripragada | Rezolute | 56 | |
| Gopal MBBS | Rezolute | N/A | |
| Elizabeth Gordon | Design Therapeutics | N/A | |
| Joshua JD | AN2 Therapeutics | 46 | |
| Dr MBA | Acrivon Therapeutics Common | N/A | |
| MS MBA | Rezolute | 50 | |
| Edward Samuel | Achilles Therapeutics PLC | N/A | |
| Zamaneh MD | Tff Pharmaceuticals | 60 | |
| Jannik Andersen | Tango Therapeutics | N/A | |
Management Performance
| Return On Equity | -3.39 | ||||
| Return On Asset | -0.65 |
Orgenesis Leadership Team
Elected by the shareholders, the Orgenesis' board of directors comprises two types of representatives: Orgenesis inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Orgenesis. The board's role is to monitor Orgenesis' management team and ensure that shareholders' interests are well served. Orgenesis' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Orgenesis' outside directors are responsible for providing unbiased perspectives on the board's policies.
| David Sidransky, Director | ||
| Osher Rheinisch, General Officer | ||
| Yaron Adler, Director | ||
| Pierre Lammeretz, Interim Officer | ||
| Neil Reithinger, CFO, Treasurer and Secretary | ||
| Joseph Carpinelli, Chief Octomera | ||
| Etti Hanochi, Director | ||
| Hugues Bultot, Director | ||
| Chris Buyse, Director | ||
| Dan Slonim, COO Israel | ||
| Sarah Ferber, Chief Scientific Officer | ||
| Vincent Vandamme, VP Strategy | ||
| Victor Miller, Chief Officer | ||
| Neil CPA, S CFO | ||
| Shimon Hassin, Chief Officer | ||
| Marie Bouillez, Director | ||
| Efrat Kunik, Chief Officer | ||
| Scott Carmer, CEO of Orgenesis Maryland Inc | ||
| Evan Fishman, Chief Officer | ||
| Guy Yachin, Director | ||
| Vered MSc, CEO Board | ||
| Vered Caplan, Chairman of the Board, Interim President and CEO | ||
| Pr Ferber, Founder Officer |
Orgenesis Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Orgenesis a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -3.39 | ||||
| Return On Asset | -0.65 | ||||
| Operating Margin | (48.42) % | ||||
| Current Valuation | 37.14 M | ||||
| Shares Outstanding | 34.34 M | ||||
| Shares Owned By Insiders | 20.35 % | ||||
| Shares Owned By Institutions | 6.56 % | ||||
| Number Of Shares Shorted | 299.69 K | ||||
| Price To Earning | 7.52 X | ||||
| Price To Book | 1.39 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Orgenesis. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. For more information on how to buy Orgenesis Stock please use our How to Invest in Orgenesis guide.Note that the Orgenesis information on this page should be used as a complementary analysis to other Orgenesis' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Complementary Tools for Orgenesis Stock analysis
When running Orgenesis' price analysis, check to measure Orgenesis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Orgenesis is operating at the current time. Most of Orgenesis' value examination focuses on studying past and present price action to predict the probability of Orgenesis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Orgenesis' price. Additionally, you may evaluate how the addition of Orgenesis to your portfolios can decrease your overall portfolio volatility.
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Bonds Directory Find actively traded corporate debentures issued by US companies |
Is Orgenesis' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Orgenesis. If investors know Orgenesis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Orgenesis listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.91) | Revenue Per Share 0.018 | Quarterly Revenue Growth (0.99) | Return On Assets (0.65) | Return On Equity (3.39) |
The market value of Orgenesis is measured differently than its book value, which is the value of Orgenesis that is recorded on the company's balance sheet. Investors also form their own opinion of Orgenesis' value that differs from its market value or its book value, called intrinsic value, which is Orgenesis' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Orgenesis' market value can be influenced by many factors that don't directly affect Orgenesis' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Orgenesis' value and its price as these two are different measures arrived at by different means. Investors typically determine if Orgenesis is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Orgenesis' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.